Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
INCA033989 + Ruxolitinib for Myeloproliferative Disorder
Recruiting1 awardPhase 1
Toronto, Ontario
This trial is testing a new drug called INCA033989, alone or with ruxolitinib, in patients with a type of blood cancer. The goal is to find the safest dose and see how well patients can tolerate it. Ruxolitinib is a medication used to treat myelofibrosis.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service